Clinical Trials

/Clinical Trials

Apalutamide Looking Good as Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC)  usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) [...]

Olaparib – Effective for Certain Genetic Metastatic Prostate Cancer Strains

I have talked a lot about our need to take the next step in clinical care, understanding the best sequencing of our drugs. Since we have a number of new drugs to treat advanced prostate cancer we now need to better understand which drugs should be used in which men as well as their proper [...]

Soon To Launch in Dublin – GAP4 Clinical Trial of Exercise for Men with Advanced Prostate Cancer

Can exercise improve the quality of life of men with advanced prostate cancer and also extend their survival? To help answer this question a major new global trial known as GAP4 has been launched in Dublin, Ireland. The trial has a goal of recruiting 866 men from seven countries, including Ireland. The trial will be [...]

Doing Away with Some of the Myths Surrounding Clinical Trials

Clinical trials are vital if we expect to continue to see improvements in the treatments and medications that are available.  Unfortunately, there are some historical abuses in clinical trials so many people do approach them with a level of distrust.  In contemporary times the clinical trial system has many safeguards that did not exist even [...]

NCI Opens New Trial – Understanding Genetic Similarities In Different Cancers

The National Cancer Institute (NCI) announced a new trial to evaluate genetic similarities in a variety of cancer types. I think that this is a great trial, which those of us who might qualify for it should think about participating. Increasingly we are thinking that to define (name) a cancer just upon the affected body [...]

We Need Your Story To Save The CDMRP – If You Have Benefitted From Xfigo, Xtandi or Zytiga Let Me Know

Most people don't know the many advances that the Department of Defense Congressionally Directed Medical Research Program (DOD PCRP) has brought to the PROSTATE CANCER COMMUNITY.  Did you know that the program is directly responsible for funding the initial development of three of the very new drugs we have available? The DOD PCRP is directly [...]

It Maybe Time To Change The Dosing Schedule Of Zoledronic Acid To Every 12 Weeks

In a presentation at the ASCO Annual Meeting,  Dr. Andrew Himelstein, MD, FACP of the Helen F. Graham Cancer Center & Research Institute, presented the results of a trial evaluating Zoledronic Acid (Zometa) at a dosing schedule of every 12 weeks as opposed to the current standard of care of every 4 weeks. The trial included [...]

Is Advanced Prostate Cancer Changing? The Evolution of Metastatic Castrate Resistant Prostate Cancer And The Need To Make Some Research Changes

Metastatic castration-resistant prostate cancer (mCRPC) is known as a cancer that more often than not metastasizes to the bone. Less often it moves to nonosseous sites (soft tissue sites like lymph nodes, liver and lung). The last few years has seen the development of new drugs that extend the survival of men. Because of these [...]

Updated Overall Survival Data from a Phase 3 Trial of Ipilimumab vs. Placebo in Men Post Chemotherapy Receiving Radiation Therapy – Still Needs Time

Presented in a poster at the recent European Society of Medical Oncologist (ESMO) there was a data update of the phase 3 clinical trial (CA184-043) which evaluated overall survival (OS) in men having radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. Initially, this trial did not meet its endpoint [...]

On The Horizon – Tasquinimod – Immunotherapy & An Anti-Angiogenic Agent

In my commitment to report “On the Horizon” treatments for advanced prostate cancer today I will discuss an investigational treatment known as Tasquinimod. It is an experimental treatment that is both an immunotherapy and anti-angiogenic agent (designed to prevent the development of blood vesicles which would feed a tumor allowing its growth). In phase 2 [...]